NSCLC

January 25, 2023

1 out 3 Medicaid patients who might have benefited from targeted therapy —mainly Tagrisso and Alecensa — for metastatic lung cancer did not receive it, according to estimates by a trio Harvard-affiliated researchers.

September 27, 2021

Judging by common end points such as overall survival and progression-free survival, results of a network meta-analysis show that Keytruda in combination with platinum-based chemotherapy achieves the best results among the immune checkpoint inhibitor therapies used to treat advanced nonsmall cell lung cancer.

September 14, 2021

Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.

September 09, 2021

A genomic analysis of the lung cancer tumors of 232 never smokers grouped them into three categories with musical names: piano, mezzo-forte and forte.

September 01, 2021

Though the study did not meet its endpoint, the strategy behind it remains under investigation.

August 02, 2021

Newly approved drugs put the brakes on particular “driver mutations,” that when unimpeded, rev up the runaway cell growth and division that characterizes cancer.

August 02, 2021

Patients with high amplification of the MET gene had a response rate of 38.1%, more than twice the response rate of those with medium amplification.

July 26, 2021

Study shows that nonsmall cell lung cancer patients who smoke but quit after their diagnosis have better overall survival, progression-free survival than patients who continue to smoke.

July 19, 2021

When wondering what step to take first after learning of your cancer diagnosis, assembling the right care team and creating a treatment plan designed uniquely is important to get you on the right track. Comprehensive biomarker testing can then help identify your type of lung cancer and help move steps forward for proper care.

July 06, 2021

Sands ,a medical oncologist who specializes in lung cancer, says the false discovery has been misconstruted as a false positive rate. He also makes a case for early detection and new USPSTF as working to correct disparities.